SDS Optic (SDS)

Executive Summary

SDS Optic is a Polish diagnostics company developing inPPROBE®, a novel point-of-care technology that combines photonics with molecular biology to detect HER2 expression. This approach aims to complement standard immunohistochemistry (IHC) and in situ hybridization (ISH) testing, potentially improving access to targeted therapies for cancer patients. Currently in the pre-clinical stage, the company is based in Lublin, Poland, and was founded in 2006. Its technology addresses a critical gap in diagnostics by offering a rapid, cost-effective, and decentralized solution for HER2 status determination, which is essential for guiding treatment decisions in breast and gastric cancers. While still early-stage, the innovative combination of photonics and molecular detection could disrupt traditional central lab testing. The company's progress and future milestones will be key to assessing its commercial viability and impact on precision oncology.

Upcoming Catalysts (preview)

• Q3 2026Preclinical proof-of-concept data publication70% success
• Q4 2026Partnership or licensing agreement with diagnostics or pharma company40% success
• Q1 2027Grant or non-dilutive funding for clinical development60% success